SequelSEC

Boundless Bio, Inc. BOLD

Pharmaceutical Preparations · CIK 0001782303 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$24.38M
Fiscal year ended 2026-06-30
Free cash flow
-$21.01M
Fiscal year ended 2026-06-30

Boundless Bio, Inc. (BOLD) reported net income of -$23.69M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Boundless Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Boundless Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$24.38M-$14.48M-$14.00M-$15.15M-$17.06M-$17.34M-$18.28M-$18.72M-$19.39M-$16.88M
Net income-$23.69M-$13.56M-$12.88M-$13.88M-$15.68M-$15.76M-$16.45M-$16.51M-$16.98M-$15.43M
Research & development$13.97M$9.73M$9.82M$10.67M$12.22M$12.14M$13.31M$14.09M$14.74M$13.13M
Weighted-average diluted sharesshares 22.45Mshares 22.41MUnavailableshares 22.39Mshares 22.36Mshares 22.30MUnavailableshares 22.25Mshares 22.02Mshares 1.26M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.06$-0.60Unavailable$-0.62$-0.70$-0.71Unavailable$-0.74$-0.77$-12.27
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.41M$4.74M$4.18M$4.48M$4.84M$5.20M$4.96M$4.63M$4.66M$3.75M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Boundless Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$20.21M$17.48M$17.87M$14.98M$14.70M$15.12M$26.59M$40.21M$31.36M$25.14M
Total assets$73.74M$140.97M$157.06M$168.72M$179.45M$191.24M$206.41M$175.09M$188.20M$117.08M
Current assets$73.65M$94.62M$109.61M$120.16M$129.69M$140.36M$154.39M$170.45M$183.13M$112.16M
Total liabilities$7.77M$54.59M$58.40M$58.55M$56.76M$54.65M$55.77MUnavailableUnavailableUnavailable
Current liabilities$7.77M$9.58M$12.54M$11.84M$9.21M$6.34M$8.14M$10.01M$8.96M$10.64M
Total equity incl. NCI$65.98M$86.38M$98.65M$110.17M$122.69M$136.59M$150.64M$165.08M$179.25M-$141.18M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$247.62M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.05M$2.04M$1.49M$1.14M$2.29M$1.37M$1.27M$2.54M$1.69M$2.94M

Cash flow

Boundless Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$20.97M-$14.97M-$10.11M-$10.20M-$11.83M-$14.53M-$15.56M-$13.27M-$16.24M-$15.78M
Capital expenditures$38.00K$8.00K$424.00K$15.00K$48.00K$59.00K$466.00K$483.00K$1.50M$83.00K
Investing cash flow$23.07M$14.59M$12.97M$10.48M$11.29M$3.06M$1.82M$22.13M-$68.19M$18.14M
Financing cash flowUnavailableUnavailable$24.00K$0UnavailableUnavailable$113.00K-$13.00K$90.65M-$924.00K
Net change in cash$2.17M-$385.00K$2.89M$283.00K-$420.00K-$11.47M-$13.63M$8.85M$6.22M$1.44M
Stock-based compensation$3.22M$1.37M$1.33M$1.30M$1.69M$1.80M$2.01M$2.04M$2.14M$1.33M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.30M$284.00K$400.00K$300.00K$300.00K$317.00K$300.00K$300.00K$300.00K$263.00K

Derived

Boundless Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$21.01M-$14.98M-$10.53M-$10.21M-$11.88M-$14.59M-$16.03M-$13.75M-$17.74M-$15.86M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.48x9.87x8.74x10.14x14.08x22.15x18.98x17.03x20.45x10.54x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BOLD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.